©TheCanadian Journal ofUrology™: International Supplement, April 2014
92
Practical guide tobonehealth in the spectrumof advancedprostate cancer
39.Lipton A, Steger GG, Figueroa J et al. Randomized active-
controlledphase II studyof denosumab efficacy and safety in
patientswithbreastcancer-relatedbonemetastases.
JClinOncol
2007;25(28):4431-4437.
40.vonMoos R, Body JJ, Egerdie B et al. Pain and health-related
qualityof life inpatientswithadvancedsolid tumoursandbone
metastases: integrated results from three randomized, double-
blind studies of denosumab and zoledronic acid.
Support Care
Cancer
2013;21(12)3497-3507.
41.SaadF, Eastham J.Zoledronicacid improves clinical outcomes
when administeredbefore onset of bonepain inpatientswith
prostate cancer.
Urology
2010;76(5):1175-1181.
42.Hadji P,AaproM,CostaL,GnantM.Antiresorptive treatment
options andbone health in cancer patients-safetyprofiles and
clinical considerations.
CancerTreatRev
2012;38(6):815-824.
43.Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose
studyof denosumab inpatientswithvarious degrees of renal
impairment.
J BoneMinerRes
2012;27(7):1471-1479.
44.AgencyEM.EUSmPC03/09/2012Xgeva-EMEA/H/C/002173
-IAIN/0012/G.
_
GB/document_library/EPAR_-_Product_Information/
human/002173/WC500110381.pdf.AccessedOctober20,2013.
45.MiglioratiCA,WooSB,Hewson I et al.Asystematic reviewof
bisphosphonate osteonecrosis (BON) in cancer.
Support Care
Cancer
2010;18(8):1099-1106.
46.HinchyNV, JayaprakashV, RossittoRAet al.Osteonecrosisof
the jaw - prevention and treatment strategies for oral health
professionals.
OralOncol
2013;49(9):878-886.
47.Edwards BJ, Hellstein JW, JacobsenPL, Kaltman S,MariottiA,
MiglioratiCA.Updatedrecommendationsformanagingthecare
of patients receivingoral bisphosphonate therapy: an advisory
statement from the American Dental Association Council on
ScientificAffairs.
JAmDentAssoc
2008;139(12):1674-1677.
48.Smith MR, Kabbinavar F, Saad F et al. Natural history of
rising serum prostate-specific antigen in men with castrate
nonmetastaticprostatecancer.
JClinOncol
2005;23(13):2918-2925.
49.SmithMR, Saad F, Coleman R et al. Denosumab and bone-
metastasis-freesurvival inmenwithcastration-resistantprostate
cancer: resultsofaphase3, randomised,placebo-controlledtrial.
Lancet
2012;379(9810):39-46.
50.BerrutiA,DogliottiL,TerroneCetal.Changes inbonemineral
density, lean bodymass and fat content asmeasured by dual
energy x-ray absorptiometry in patients with prostate cancer
withoutapparentbonemetastasesgivenandrogendeprivation
therapy.
JUrol
2002;167(6):2361-2367; discussion 7.
51.Higano C, Shields A, Wood N, Brown J, Tangen C. Bone
mineral density inpatientswithprostate cancerwithout bone
metastases treated with intermittent androgen suppression.
Urology
2004;64(6):1182-1186.
52.LiptonA, FizaziK, StopeckATetal. Superiorityofdenosumab
to zoledronic acid for prevention of skeletal-related events:
a combined analysis of 3 pivotal, randomised, phase 3 trials.
Eur JCancer
2012;48(16):3082-3092.
53.Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes
MR.Adjuvant therapywith oral sodium clodronate in locally
advanced and metastatic prostate cancer: long-term overall
survival results from the MRC PR04 and PR05 randomised
controlled trials.
LancetOncol
2009;10(9):872-876.
54.NelsonJB,LoveW,ChinJLetal.Phase3,randomized,controlled
trial of atrasentan in patients with nonmetastatic, hormone-
refractoryprostate cancer.
Cancer
2008;113(9):2478-2487.
55.Miller K, Moul JW, Gleave M et al. Phase III, randomized,
placebo-controlledstudyofonce-dailyoralzibotentan (ZD4054)
in patients with non-metastatic castration-resistant prostate
cancer.
ProstateCancerProstaticDis
2013;16(2):187-192.
